| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
| Targets |
(S)-1-Boc-3-aminopiperidine does not have a defined pharmacological target of its own, as it is a synthetic intermediate rather than a drug substance. However, it is used as a key intermediate in synthesizing various pharmaceuticals, particularly in developing drugs targeting neurological disorders. The compound is also used to prepare selective noncovalent inhibitors of the bacterial cysteine protease IdeS. The Boc-protected piperidine scaffold is a common motif in medicinal chemistry for constructing biologically active compounds.
|
|---|---|
| ln Vitro |
In vitro, (S)-1-Boc-3-aminopiperidine is primarily used as a chemical reagent and synthetic intermediate. It is employed in the synthesis of various pharmaceutical compounds that are subsequently tested in in vitro assays. The compound's properties allow it to improve the solubility and absorption of active pharmaceutical ingredients, making it valuable in drug formulation processes. As a chiral building block, it is used in the preparation of enantiomerically pure drug candidates for in vitro screening.
|
| ln Vivo |
In vivo activity data for (S)-1-Boc-3-aminopiperidine itself are not available, as the compound is not intended for direct in vivo administration. Rather, it is a precursor used in the synthesis of drug candidates that are subsequently evaluated in animal models. The compound's in vivo relevance is indirect, through the biological activities of the final pharmaceutical compounds derived from it, particularly those targeting neurological disorders and bacterial infections.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding studies, (S)-1-Boc-3-aminopiperidine is not typically evaluated as a test compound itself. Instead, it serves as a reagent for the synthesis of test compounds. The compound's properties include a molecular weight of 200.28 g/mol, a melting point of 21-25°C, and a flash point of 122°C. The Boc-protected amine provides a handle for selective deprotection and functionalization in medicinal chemistry.
|
| Cell Assay |
For in vitro cell-based experiments, (S)-1-Boc-3-aminopiperidine is used as an intermediate in the synthesis of compounds that are tested in cell viability, proliferation, and cytotoxicity assays. The compound itself is not typically evaluated in cell-based assays. Standard cell culture protocols for test compounds synthesized from this intermediate involve dissolving the final product in DMSO and diluting to working concentrations in appropriate cell culture medium.
|
| Animal Protocol |
In vivo animal studies using (S)-1-Boc-3-aminopiperidine are conducted on the final drug compounds synthesized from it, not on the intermediate itself. For pharmaceutical candidates derived from this building block, efficacy studies would typically be performed in mouse models of the relevant disease (e.g., neurological disorder models). Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection, with appropriate pharmacokinetic and pharmacodynamic endpoints.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (S)-1-Boc-3-aminopiperidine as a standalone compound are not characterized in the literature. The compound has a molecular weight of 200.28 g/mol, which is within the favorable range for oral bioavailability. As a Boc-protected amine, it is expected to have moderate lipophilicity. The compound's properties allow it to improve the solubility and absorption of active pharmaceutical ingredients. Empirical pharmacokinetic data are not available for this intermediate compound.
|
| Toxicity/Toxicokinetics |
(S)-1-Boc-3-aminopiperidine is a research chemical and should be handled with appropriate laboratory safety precautions. As a piperidine derivative, it may pose risks of skin and eye irritation. The compound has a flash point of 122°C and should be stored in a cool, dry place. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a fume hood.
|
| Additional Infomation |
(S)-1-Boc-3-aminopiperidine ((S)-(+)-3-Amino-1-boc-piperidine, CAS 625471-18-3) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are in pharmaceutical development as a key chiral building block for drugs targeting neurological disorders and as a reagent for preparing inhibitors of bacterial cysteine protease IdeS. The compound's properties allow it to improve the solubility and absorption of active pharmaceutical ingredients. No clinical trials or approved indications exist for this compound. It is intended for laboratory research use only.
|
| Molecular Formula |
C10H20N2O2
|
|---|---|
| Molecular Weight |
200.28
|
| Exact Mass |
200.152
|
| CAS # |
625471-18-3
|
| PubChem CID |
1501975
|
| Appearance |
Colorless to light yellow liquid（Density：1.02 g/cm3）
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
277.3±33.0 °C at 760 mmHg
|
| Flash Point |
121.5±25.4 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.484
|
| LogP |
0.71
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
14
|
| Complexity |
211
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)(C)OC(=O)N1CCC[C@@H](C1)N
|
| InChi Key |
AKQXKEBCONUWCL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H20N2O2/c1-10(2,3)14-9(13)12-6-4-5-8(11)7-12/h8H,4-7,11H2,1-3H3
|
| Chemical Name |
tert-butyl 3-aminopiperidine-1-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (499.30 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.48 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (12.48 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.48 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9930 mL | 24.9650 mL | 49.9301 mL | |
| 5 mM | 0.9986 mL | 4.9930 mL | 9.9860 mL | |
| 10 mM | 0.4993 mL | 2.4965 mL | 4.9930 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
